Abstract-Treatment of human aortic endothelial cells (EC) with minimally oxidized LDL (or minimally modified LDL, MM-LDL) produces a specific pattern of endothelial cell activation distinct from that produced by LPS, tumor necrosis factor-␣, and interleukin-1, but similar to other agents that elevate cAMP. The current studies focus on the signal transduction pathways by which MM-LDL activates EC to bind monocytes. We now demonstrate that, in addition to an elevation of cAMP, lipoxygenase products are necessary for the MM-LDL response. [1] [2] [3] Exposure of EC to the major cytokines, tumor necrosis factor-␣ (TNF-␣) and interleukin-1 (IL-1), and lipopolysaccharide (LPS) increased transcription of intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin, adhesion molecules that promote both neutrophil and monocyte binding. 4, 5 In contrast, MM-LDL selectively stimulates EC to bind monocytes but not neutrophils 2 by an alternatively spliced variant of fibronectin 6 and without increasing expression levels of ICAM-1, VCAM-1, or E-selectin. 3 We have previously demonstrated that treatment of EC with MM-LDL caused a rapid increase in cAMP that was necessary for the induction of monocyte binding by MM-LDL. 1 We also found that other agents that increase cAMP, including cholera toxin, pertussis toxin, and dibutyryl cAMP, had a similar effect to MM-LDL; these agents stimulated monocyte but not neutrophil binding to EC without increasing expression of ICAM-1, VCAM-1, and E-selectin. 1 Taken together these observations suggest that MM-LDL and cytokines activate distinct signal transduction pathways. These separate pathways may determine the differences between acute inflammation mediated by neutrophils and chronic inflammation mediated by monocytes.
P revious studies by our group have demonstrated that minimally modified LDL (MM-LDL) produces a distinct pattern of endothelial cell (EC) activation. [1] [2] [3] Exposure of EC to the major cytokines, tumor necrosis factor-␣ (TNF-␣) and interleukin-1 (IL-1), and lipopolysaccharide (LPS) increased transcription of intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin, adhesion molecules that promote both neutrophil and monocyte binding. 4, 5 In contrast, MM-LDL selectively stimulates EC to bind monocytes but not neutrophils 2 by an alternatively spliced variant of fibronectin 6 and without increasing expression levels of ICAM-1, VCAM-1, or E-selectin. 3 We have previously demonstrated that treatment of EC with MM-LDL caused a rapid increase in cAMP that was necessary for the induction of monocyte binding by MM-LDL. 1 We also found that other agents that increase cAMP, including cholera toxin, pertussis toxin, and dibutyryl cAMP, had a similar effect to MM-LDL; these agents stimulated monocyte but not neutrophil binding to EC without increasing expression of ICAM-1, VCAM-1, and E-selectin. 1 Taken together these observations suggest that MM-LDL and cytokines activate distinct signal transduction pathways. These separate pathways may determine the differences between acute inflammation mediated by neutrophils and chronic inflammation mediated by monocytes.
To elucidate the signal transduction mechanisms by which MM-LDL activates the endothelium, we have examined the role of lipoxygenase (LO) metabolites in the actions of MM-LDL. The LO pathway was investigated because several previous studies had suggested that responses to oxidation were mediated by this pathway. 7, 8 
Methods

Cell Preparation
Human aortic EC (HAEC) were isolated from aortic specimens and cultured as previously described. 9 Human monocytes were isolated by the modified Recalde method as described previously. 10 
Intracellular Calcium Measurements
Intracellular calcium (Ca i ) measurements were performed as previously described. 11 In brief, HAEC were grown to confluence on glass coverslips coated with Cell-Tak (Becton Dickinson) and 3 g/mL of a collagen derivative (Vitrogen; Celtrix). Before the experiments, HAEC were incubated for 30 minutes in 2 mol/L Fura-2 AM (Molecular Probes) in serum-free Hanks buffered salt solution (HBSS) at 37°C. The cells were then washed in Fura-free HBSS and kept in the dark at room temperature for 30 minutes before the start of the experiment to allow for deesterification of the fluorescent dye. The video image was digitized using the Axon Imaging Workbench 2 (Axon Instruments, Inc). A 5ϫ5 pixel area of an EC was processed by dividing each even field by its corresponding odd field to produce a ratiometric measure of relative Ca i concentration. Each point represents the average of 4 to 10 consecutive frames (obtained at video speed of 30/s) of the fluorescence ratio. Background fluorescence represented less than 5% of the total fluorescence at 335 and 405 nm and was not subtracted from each image before calculation of the fluorescence ratio.
Quantitation of Arachidonic Acid Metabolites
For analysis of labeled phospholipids HAEC were incubated in M199 and 10% FCS with 5 Ci/mL 3 H-arachidonate for 24 hours. To remove extracellular free arachidonate, HAEC were rinsed 3 times and incubated with 0.05% BSA in M199 for 2 hours and subsequently in M199 and 10% FCS for 2 hours. This method has been previously used for labeling phospholipids in porcine aortic EC. 12 The medium was tested to ensure that essentially all the free arachidonate had been washed away. The cells that had been labeled with arachidonate and washed were then placed in fresh medium with or without 100 g/mL of native LDL or MM-LDL for 4 hours. Lipids were extracted from medium and cells before and after this 4-hour incubation using chloroform methanol. 13 After that time medium and cells were collected. To determine the distribution of labeled arachidonate, the chloroform and methanol were removed by drying under a stream of nitrogen, and chloroform was added to resuspend the lipids. These were applied to an aminopropyl column; neutral lipids, phospholipids, and fatty acids were collected separately as described previously. 14 For analysis of arachidonate metabolites, lipid extracts from medium and cells were collected and processed as previously described. 12, 15 In brief, lipids from the medium were prepared by chloroform methanol extraction. Lipid extracts from media were dried, resuspended, and placed onto a solid-phase C18 column. The column was washed with water, and arachidonate and its metabolites were collected in ethyl acetate; thus only free fatty acids were analyzed. In initial studies, lipid extract from cells was processed in the same manner but no lipid was detected in the free fatty acid fractions. Thus for further studies lipid extracts from cells were hydrolyzed with 0.2N methanolic NaOH in the dark under N 2 and in the presence of the antioxidant propyl gallate to prevent nonspecific oxidation. The hydrolyzed lipids were then collected and placed onto the C18 solid-phase column and processed as described for the medium. Reverse-phase high-performance liquid chromatography (HPLC) was performed as previously described. 16 Samples were placed onto a C18 column (Bio-Sil HL 90-5S 250ϫ4.6 mm) and eluted using a series of isocratic solutions of 0.1% trifluoroacetic acid (TFA), water, and acetonitrile. Oneminute fractions were collected and radioactivity determined. The column elution profile was determined using standards of 12S-hydroxyeicosatetraenoic acid (12S-HETE), 15-HETE, 11,12-epoxyeicosatrienoic acid (11,12-EET), and 6-keto-PGF 1␣ (Biomol Research Laboratories). The order of elution of the standard was similar to that shown previously. 16 Recoveries from the reversephase column were calculated to be approximately 80%.
In separate studies arachidonate metabolites were measured by radioimmunoassay (RIA). These assays for 12-HETE and 6-keto-PGF 1␣ were performed as previously described. 12, 15 Preparation of LDL and MM-LDL LDL was isolated by density-gradient centrifugation. To avoid oxidation of native LDL, blood was drawn into sodium citrate and all solutions were supplemented with 0.01% EDTA. Thioburbituric acid reactive substances (TBARS) levels were less than 1 nmol ⅐ L Ϫ1 ⅐ mg Ϫ1 LDL protein. MM-LDL was prepared by iron oxidation as described previously. 17 TBARS levels were 2 to 3 nmol ⅐ L Ϫ1 ⅐ mg
Ϫ1
protein and beta carotene was decreased by 90%. Both native LDL and MM-LDL were stored with 80 mol/L BHT and 0.01% EDTA.
The exact concentration of MM-LDL to which EC are exposed in the subintimal space within the vessel wall in vivo is not known; however, if the serum concentration of LDL is 150 mg/dL, then 100 g/mL represents Ϸ7% of the serum levels of LDL. It is possible that MM-LDL is concentrated or "trapped" within the subintimal space as suggested by electron microscopic images of the vessel wall in atherosclerotic lesions. 18 Because all preparations of MM-LDL stimulated monocyte binding at 100 g/mL, we have included this concentration of MM-LDL in all of our studies.
Monocyte Adhesion Assay
These assays were performed essentially as described previously. 1 HAEC in M199 containing 10% FBS were grown to confluency in 48-well dishes and exposed to LDL or MM-LDL for 4 hours at 37°C. 
cAMP Measurements
cAMP measurements were performed as described previously by our group using the cAMP RIA kit (Amersham Corp). 1
Statistical Analysis
Data are presented as meanϮSE and analyzed using the Student's t test. Differences were considered significant at PϽ0.05.
Results
Lipoxygenase Inhibitors but not a Cyclooxygenase Inhibitor Block the Induction of Monocyte Binding to Endothelial Cells by MM-LDL
EC were treated for 30 minutes with the LO inhibitors, CDC (10 Ϫ8 mol/L) or ETYA (10 Ϫ8 mol/L), or the cyclooxygenase inhibitor indomethacin (10 Ϫ8 mol/L). LDL or MM-LDL (100 g/mL) in M199 containing 10% FBS was then added for 4 hours. After treatment, wells were washed and the monocyte adhesion assay was performed. MM-LDL but not LDL at 100 g/mL increased the number of monocytes bound to the monolayer by 118Ϯ13% (Figure 1, top) . MM-LDL at 50 g/mL but not 20 g/mL also caused a significant increase in monocyte binding (47Ϯ5% increase at 50 g/mL, 5Ϯ4% increase at 20 g/mL). Pretreatment with ETYA or CDC significantly blunted this increase in monocyte binding in response to MM-LDL to 33Ϯ4% and 23Ϯ4%, respectively, whereas indomethacin had no effect (118Ϯ5%). There was no effect of the inhibitors alone on monocyte binding to untreated cells (data not shown). The inhibitory effect of CDC on MM-LDL induction of monocyte binding could be completely reversed by the addition of 10 Ϫ8 mol/L 12(S)-HETE, a major arachidonate metabolite of LO in EC treated by MM-LDL (Figure 1, bottom) .
Lipoxygenase Inhibitors do not Block the cAMP Increase Induced by MM-LDL
We have previously shown that MM-LDL but not LDL treatment of EC causes a rapid increase in levels of cAMP. 1 This increase was necessary for the effects of MM-LDL on monocyte binding because inhibition of protein kinase A by N-(2-
[Methylamino]ethyl)-5-isoquinoline-sulfonamide prevented the induction of monocyte binding by MM-LDL. 1 To determine whether the effects of CDC and EYTA were mediated by a change in the levels of cAMP in MM-LDL-treated cells, EC monolayers were treated for 1 hour with MM-LDL in the presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX). We have previously shown that 1 hour represents the time of the maximal cAMP response induced by MM-LDL. 1 One hour of MM-LDL but not LDL treatment caused a 115Ϯ5% increase in cAMP (Figure 2 ). EC pretreated with CDC actually exhibited higher levels of cAMP after MM-LDL treatment (194Ϯ5% increase) whereas EC pretreated with ETYA had a similar increase to that seen with MM-LDL alone. The inhibitors did not affect the levels of cAMP in untreated cells (data not shown). Therefore LO inhibitors, which prevented the induction of monocyte binding by MM-LDL, did not prevent the MM-LDL-induced increase in cAMP.
MM-LDL Increases the Metabolism of Arachidonic Acid and the Production of Lipoxygenase Products by Endothelial Cells
To determine the effect of MM-LDL on arachidonate metabolism, EC were labeled for 24 hours with 3 H-arachidonic acid. The cells were then extensively rinsed and incubated for 1 hour in medium containing BSA to remove free arachidonic acid. After these rinses, less than 1% of the 3 H-arachidonate remained as the free fatty acid, 2.5% was incorporated into triglycerides, and approximately 96% was incorporated into phospholipid. These labeled cells were incubated for 4 hours with or without 100 g/mL of native LDL or MM-LDL. Arachidonate and arachidonate metabolites were released into the medium as demonstrated by HPLC (Figure 3, top) . The major metabolites were 12-HETE and a mode correlating with 11,12-EET (referred to as 11,12-EET). There were lesser amounts of 15-HETE and an unknown, highly lipophilic metabolite. Very little prostaglandin (which elutes in frac- tions earlier than the HETE or EET) was released from these cells. MM-LDL treatment of EC for 4 hours increased arachidonate release and also significantly increased levels of 11,12-EET, the unknown metabolite, and, to a smaller extent, 12S-HETE in the medium (Figure 4, top) . The profiles and levels of cell-associated arachidonate metabolites were also examined after the 4-hour incubation period. In contrast to the medium, less than 4% of labeled cell-associated arachidonate was unesterified; thus cellular lipids were analyzed after hydrolysis. As demonstrated by HPLC, the major peak of cell-associated arachidonate metabolites contained 12-HETE (Figure 3, bottom) . Lower amounts of 11,12-EET were also present. Label was also found in 2 unidentified nonpolar peaks. The amounts of 12-HETE as well as 11,12-EET were significantly increased in cells treated with MM-LDL but not with native LDL (Figure 4, bottom) . In a separate set of experiments using RIA, we observed that 12-HETE synthesis and release were increased in HAEC treated as above with MM-LDL but not LDL (Table) . Greater increases were seen in this RIA compared with the labeling studies, probably because of variability in EC from different donors. Treatment of EC with concentrations of CDC and ETYA, which blocked induction of monocyte binding by MM-LDL, also inhibited MM-LDL-induced 12-HETE formation as measured by HPLC (CDC, Ϫ78Ϯ6%; ETYA, Ϫ81Ϯ5% compared with cells not exposed to CDC or ETYA). Levels of 11,12-EET were unaffected by CDC or ETYA (data not shown).
MM-LDL Increases Endothelial Intracellular Calcium Levels
One established mechanism by which arachidonate metabolism is stimulated is through increases in Ca i and stimulation of cytosolic phospholipase A 2 (cPLA 2 ). 19 We therefore tested the effects of MM-LDL on EC Ca i . As seen in Figure 5 , 100 g/mL of MM-LDL led to a rapid increase in EC Ca i . To determine whether this increase in EC Ca i , was mediated by release from 
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Cell were either untreated or treated for 4 hours with 100 g/mL native LDL or 100 g/mL of MM-LDL. Fatty acids from medium and hydrolyzed cell lysates were tested from duplicate dishes using RIA. These data represent 3 separate experiments.
intracellular stores or influx from the extracellular space, we tested the effect of 100 g/mL of MM-LDL on EC Ca i in the presence and absence of extracellular 5 mmol/L EGTA ( Figure  6 ). MM-LDL increased EC Ca i to a similar magnitude in both conditions, demonstrating that MM-LDL increases EC Ca i primarily by releasing calcium from intracellular stores. Because LDL also had been shown to increase Ca i in bovine aortic EC, 20 but did not lead to significant increases in monocyte binding 1 or levels of 12-HETE in human aortic EC (Table) , we compared the effects of various concentrations of LDL and MM-LDL on EC Ca i (Figure 7 ). Both MM-LDL and native LDL increased Ca i at 1, 5, 10, and 100 g/mL in a concentration-dependent manner. MM-LDL led to a small but significantly greater increase in EC Ca i compared with LDL (PϽ0.05 at each concentration tested, nϭ3). We also found that a lower dose of MM-LDL (50 g/mL), which gave an equivalent increase in EC Ca i as did 100 g/mL of LDL, induced monocyte binding whereas LDL had no effect on monocyte binding (data not shown).
Discussion
The present studies have addressed several aspects of the MM-LDL signal transduction pathway in HAEC. We have previously shown that inhibitors of protein kinase A block MM-LDL induction of monocyte binding to EC, indicating the importance of the cAMP pathway. 1 We now present evidence that the LO pathway is also necessary for the MM-LDL signal transduction pathway leading to increased monocyte binding. Pretreatment of EC with LO but not cyclooxygenase inhibitors blocked MM-LDL induction of monocyte binding without inhibiting the increase in cAMP elevation (Figure 2) . The LO inhibitors used in this study, EYTA and CDC, both have been shown to be relatively specific at the concentrations used in this study. CDC most potently inhibits 12-LO with lesser effects on 5-LO and 15-LO, and without effects on cyclooxygenase or cytochrome P450. 21 At higher concentrations than used in these experiments, EYTA can inhibit both 5-LO at 10 Ϫ8 mol/L, cytochrome P450 at 10 Ϫ7 mol/L, and cyclooxygenase at 10 Ϫ6 mol/L. 22 In our studies we have demonstrated an approximately 80% inhibition of 12-HETE production by CDC and ETYA. Thus we conclude that the LO inhibitors at the concentrations used in these experiments specifically blocked 12-LO activity.
To gain more insight into role of the LO pathway in MM-LDL induction of monocyte binding, we labeled EC with 3 H-arachidonate and examined arachidonate release and production of oxygenated derivatives of arachidonate in untreated and MM-LDL-treated EC. Arachidonic acid is the precursor for several eicosanoids with potent biological effects including inflammation and cell growth. 23 The major oxidative products released into the medium under unstimulated conditions were 11,12-EET (a product of the cytochrome P450 pathway) and 12-HETE ( Figure 3, top) ; lower levels of 15-HETE and 6-keto-PGF 1␣ were also released into the medium. The low level of prostaglandin release most likely relates to the fact that these cells were used at passage 8 as others have shown a steady loss of cyclooxygenase products in passaged EC. 24 In the cytoplasm most of the oxidized product within the cells was 12-HETE with lower levels of 11,12-EET. It should be noted that although the product identified as 11,12-EET migrates with authentic 11,12-EET in our HPLC system, it has not been chemically identified as 11,12-EET. Except for the lack of prostaglandins, the arachidonate metabolites released were similar to those found in bovine coronary EC. 25 Treatment of EC with MM-LDL caused a 60% increase in the release of arachidonate into the medium. This was associated with a significant increase in cell-associated 12-HETE and, to a lesser extent, medium content of 12-HETE ( Figure 4 , top and bottom, Table) . In a previous publication, we demonstrated that EC contain 12-LO but not 15-LO, 26 the major product of which is 12-HETE. These studies demonstrate that 12-HETE can reverse the effect of CDC on MM-LDL-induced monocyte binding (Figure 1, bottom) . Because 12-HETE is elevated in MM-LDL-treated cells and can mimic the effect of MM-LDL on monocyte binding, 27 it is likely to be an important mediator of MM-LDL activity. Recent studies have demonstrated that the metabolites of linoleic acid, 9-hydroxyoctadeca-10,12-dienoic acid and 13-hydroxyoctadeca-9,11-dienoic acid in oxidized lipids, can activate the nuclear hormone receptor transcription factor PPAR␥ in macrophages. 28 Although PPAR␥ is expressed in high levels in adipose tissues as well as in macrophage foam cells, there appeared to be little if any expression in EC within an atherosclerotic lesion when macrophage foam cells are present. 28 Further studies, however, are required to determine whether metabolites of linoleic acid can mediate some of the biological effects of MM-LDL.
In addition to the increase in 12-HETE in EC in response to MM-LDL, we also observed a significant increase in 11,12-EET induced by treatment of EC with MM-LDL. EETs have been shown to be formed by metabolism of arachidonate by the cytochrome P450 pathway and not by LO. 29 Increased levels of 11,12-EET have been previously observed in EC treated with high concentrations of native LDL for 4 days. 30 In addition, previous studies have shown that 11,12-EET can stimulate monocyte-endothelial interactions in human umbilical vein EC. 31 This agent has been shown to cause vascular relaxation 30 and thus might be an important mediator of vascular tone in atherosclerosis, in which endothelialderived nitric oxide levels are reduced.
Treatment of EC with MM-LDL, and to a lesser extent native LDL, released calcium from internal stores ( Figure 6 ). Although an increase in Ca i by itself may cause activation of cPLA 2 and thereby contribute to arachidonate release and consequent stimulation of LO activity, 19 ,32 the present studies suggest that mechanisms in addition to increases in EC Ca i are required for arachidonate release and generation of LO products by MM-LDL. This finding is supported by the finding that native LDL at a concentration of 100 g/mL increased EC Ca i to nearly the same extent as 50 or 100 g/mL MM-LDL but did not increase levels of 12-HETE or monocyte binding. Several groups 33, 34 have documented the presence of calcium-independent PLA 2 . We conclude that an increase in Ca i is not sufficient for arachidonate release by MM-LDL.
The present studies suggest that the LO products synthesized in response to MM-LDL act downstream or parallel to cAMP in the signal transduction pathway of MM-LDL ( Figure 1, top and bottom) . We have previously presented evidence that both cAMP and MM-LDL increase nuclear factor-kappa B (NF-B) activation in HAEC. 1 In addition, several genes whose transcription is increased by MM-LDL have important NF-B elements in the promoter region. [35] [36] [37] Previous studies have shown that NF-B activation may involve reactive oxygen intermediates. 38 Inhibition of the LO pathway has been shown to decrease NF-B activation, suggesting that the products of this pathway may be involved in endothelial activation. 8 In summary, the current studies suggest that MM-LDL stimulates formation of oxygenated fatty acids by both the LO and P450 pathways. An increase in Ca i is not sufficient for the generation of arachidonate in EC exposed to MM-LDL. Finally, LO metabolites, in particular 12-HETE, appear to mediate the increase of monocyte binding to EC exposed to MM-LDL.
